Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency

Abstract Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adrenal insufficiency (AI) can be life-threatening especially in patients with d...

Full description

Bibliographic Details
Main Authors: Katsunori Manaka, Junichiro Sato, Maki Takeuchi, Kousuke Watanabe, Hidenori Kage, Taketo Kawai, Yusuke Sato, Takuya Miyagawa, Daisuke Yamada, Haruki Kume, Shinichi Sato, Takahide Nagase, Taroh Iiri, Masaomi Nangaku, Noriko Makita
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-91032-6

Similar Items